Inhibition of DNA repair with PARP inhibitors is an effective cytotoxic strategy when used in patients with tumours that are deficient in BRCA1 and BRCA2. 27 In this study, 50% (3/6) of patients with BRCA mutations showed a response of either partial response (n = 1, high-grade serous ovarian tumour) or stable disease (n = 2, pancreatic tumour and high-grade serous ovarian tumour), highlighting the preliminary activity of E7449 in patients with BRCA mutations. This evidence concerns the gene BRCA1 and neoplasm.